Basilea to accelerate repayment of Athyrium loan by Q1 2024

By Marisa Wong

Los Angeles, Dec. 20 – Basilea Pharmaceutica Ltd., Allschwil announced in a Wednesday press release that it will accelerate the repayment of its senior secured loan.

The senior secured loan from Athyrium Capital Management, LP had an initial total amount of CHF 75 million and a two-year term from September 2022 to September 2024.

The repayment started as of Q1 2023 on a quarterly basis. Basilea now plans to have the loan fully repaid by the end of Q1 2024.

Chief financial officer Adesh Kaul said, “The accelerated repayment reduces our interest payments and fees by approximately CHF 1.5 million, freeing up funds for investing into the continued expansion and progression of our pipeline of promising anti-infective drug candidates and creating long-term value for our shareholders.”

Basilea is a commercial-stage biopharmaceutical company focused on severe bacterial and fungal infections and is based in Allschwil, Switzerland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.